RGRX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 19:15):

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration...

Stats
Dagens volum	55.00
Gjennomsnittsvolum	95.00
Markedsverdi	209 576
EPS	$-0.00380 ( 2023-03-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-03	Essetifin Spa	Buy	3 750 000	Common Stock Warrant (right to buy)
2023-07-03	Essetifin Spa	Buy	0	Convertible Promissory Note (right to buy)
2022-05-17	Goldstein Allan L	Buy	480 000	Stock Option (Right to Buy)
2022-05-17	Goldstein Allan L	Buy	480 000	Stock Option (Right to Buy)
2022-05-17	Bove Mauro	Buy	240 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 98 transactions
Buy: 35 451 124 \| Sell: 5 867 027

RegeneRx Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

RegeneRx Økonomi

Annual	2022
Omsetning:	$76 761.00
Bruttogevinst:	$76 761.00 (100.00 %)
EPS:	$-0.0120

FY	2022
Omsetning:	$76 761.00
Bruttogevinst:	$76 761.00 (100.00 %)
EPS:	$-0.0120

FY	2021
Omsetning:	$76 761.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0120

FY	2020
Omsetning:	$76 761.00
Bruttogevinst:	$76 761.00 (100.00 %)
EPS:	$-0.0100

Financial Reports:

No articles found.

RegeneRx

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.